Development of health food supplements and antioxidants for controlling hyperuricemia and oxidative stress
US-2021386812-A1 · Dec 16, 2021 · US
Method for inhibiting expression of icam-1 gene
US2019307827A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019307827-A1 |
| Application number | US-201816103795-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 14, 2018 |
| Priority date | Apr 10, 2018 |
| Publication date | Oct 10, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for inhibiting the expression of ICAM-1 gene is provided, wherein the method comprises administering to a subject in need an effective amount of an euryale seed extract. The method is especially for treating, preventing or regulating diseases or physiological functions associated with ICAM-1 gene.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method for inhibiting expression of ICAM-1 gene, comprising administering to a subject in need an effective amount of an euryale seed extract. 2 . The method as claimed in claim 1 , wherein the extract is obtained by extracting an euryale seed with a polar solvent, and the polar solvent is selected from a group consisting of water, C1-C4 alcohols, and combinations thereof. 3 . The method as claimed in claim 1 , which is for inhibiting vascular endothelial inflammation, and the extract is administered to the subject as a pharmaceutical composition. 4 . The method as claimed in claim 1 , which is for treating cardiovascular diseases, preventing cardiovascular diseases, treating breast cancer, preventing breast cancer, treating adhesive capsulitis, and/or preventing adhesive capsulitis, and the extract is administered to the subject as a pharmaceutical composition. 5 . The method as claimed in claim 4 , wherein the cardiovascular disease is atherosclerosis. 6 . The method as claimed in claim 1 , which is for assisting in maintenance of vascular elasticity, and/or assisting in protection of joint, and the extract is administered to the subject as a food product composition. 7 . The method as claimed in claim 2 , which is for inhibiting vascular endothelial inflammation, and the extract is administered to the subject as a pharmaceutical composition. 8 . The method as claimed in claim 2 , which is for treating cardiovascular diseases, preventing cardiovascular diseases, treating breast cancer, preventing breast cancer, treating adhesive capsulitis, and/or preventing adhesive capsulitis, and the extract is administered to the subject as a pharmaceutical composition. 9 . The method as claimed in claim 8 , wherein the cardiovascular disease is atherosclerosis. 10 . The method as claimed in claim 2 , which is for assisting in maintenance of vascular elasticity, and/or assisting in protection of joint, and the extract is administered to the subject as a food product composition.
Assignees
Inventors
Classifications
- A61K36/62Primary
Nymphaeaceae (Water-lily family) · CPC title
- A23L33/105Primary
Plant extracts, their artificial duplicates or their derivatives · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019307827A1 cover?
- A method for inhibiting the expression of ICAM-1 gene is provided, wherein the method comprises administering to a subject in need an effective amount of an euryale seed extract. The method is especially for treating, preventing or regulating diseases or physiological functions associated with ICAM-1 gene.
- Who is the assignee on this patent?
- Tci Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K36/62. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Oct 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).